Paper Details

  1. Home
  2. Paper Details

Discovery of a PROTAC targeting ALK with in vivo activity.

Author: HouXueyan, LanSuke, LiRui, PuChunlan, ShanHuifang, YanGuoyi, YangJie, YueLin, ZhongXinxin, ZhouMeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

ALK degrader B3 showed potent selective inhibitory activity to ALK and can decrease the cellular levels of ALK fusion proteins in a concentration- and time-dependent manner in H3122 cell line. B3 also showed improved anticancer activity in vitro comparing with LDK378 and the antiproliferative activity to xenograft tumor model was acceptable.
Paper Details　
Original Abstract of the Article :
Anaplastic lymphoma kinase (ALK) was involved in the development of various cancer types. Although several ALK inhibitors have been advanced to clinical trials, the emergence of drug resistance has limited the clinical application of them. To overcome the drug resistance, proteolysis targeting chime...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejmech.2020.113150

データ提供：米国国立医学図書館（NLM）

ALK Degraders: A New Weapon in the Fight Against Cancer

The fight against cancer is an ongoing battle, and this research delves into the exciting field of proteolysis targeting chimeras (PROTACs), a revolutionary approach to drug development. This study focuses on ALK degraders, a new class of molecules designed to specifically target and degrade ALK, a protein implicated in various cancers. It's like navigating a labyrinthine cave system, seeking out and destroying the source of cancer's growth.

Targeted Degradation: A New Era in Cancer Therapy

This research presents a promising new strategy for cancer treatment, one that utilizes targeted degradation rather than traditional inhibition. It's like using a precise laser to eliminate a cancerous tumor, minimizing collateral damage to healthy cells. This study highlights the potential of ALK degraders to overcome drug resistance, a significant challenge in cancer therapy. The authors' discovery of compound B3, a potent ALK degrader with promising anti-cancer activity both in vitro and in vivo, opens up new avenues for treating ALK-driven cancers.

Hope on the Horizon: New Avenues for Cancer Treatment

This research holds immense promise for the future of cancer treatment. It offers a new weapon in the fight against these debilitating diseases, providing hope for patients and their families. The authors' work inspires us to explore novel approaches to cancer therapy, potentially leading to more effective and personalized treatments. It's like finding a hidden spring of water in the desert, a source of hope and resilience in the face of adversity.

Dr.Camel's Conclusion

The discovery of ALK degraders, particularly compound B3, represents a significant breakthrough in the fight against cancer. This research offers hope for patients and inspires further investigation into the therapeutic potential of PROTACs. It's like finding a treasure map leading to a hidden oasis of effective cancer treatments, a testament to the enduring spirit of scientific discovery.

Date :
  1. Date Completed 2021-04-23
  2. Date Revised 2021-04-23
Further Info :

Pubmed ID

33453602

DOI: Digital Object Identifier

10.1016/j.ejmech.2020.113150

Related Literature

Article Analysis
・Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.